Senolytx logo — STX develops medicines targeting damaged cells to improve hu...

Senolytx

STX develops medicines targeting damaged cells to improve human health and advance therapies to clinical trials for aging-associated diseases.

Founded 2017 Spain Spain 2 employees Grant Total: $571.43K Biopharma, Biotechnology +3

General Information

Company Name Senolytx
Founded Year 2017
Location Spain Spain +1
Founders / Decision Makers
Team member
Employees 2
Industries Biopharma, Biotechnology, Medical Devices +2
Funding Stage Grant
Social

Get notified when Senolytx moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Senolytx

Senolytx is a biopharmaceutical startup founded in 2017 with a mission to develop medicines targeting damaged cells to advance therapies for aging-associated diseases. Its slogan, "STX develops medicines targeting damaged cells to improve human health and advance therapies to clinical trials for aging-associated diseases," captures the essence of its core focus. The company, located in Boston (US) and Barcelona (Spain), operates in the Biopharma, Biotechnology, Pharmaceutical, and Robotics industries. It recently received a €71.43K Grant investment on 01 August 2018 from the EASME - EU Executive Agency for SMEs. Senolytx's dedicated efforts are directed towards advancing its portfolio of therapies to clinical trials, aiming to ultimately improve the lives of patients and families affected by aging-associated diseases. Senolytx represents a promising player in the biopharmaceutical space, with its innovative approach and strategic presence in both the US and Spain, offering a significant advantage in accessing diverse markets and resources. As a potential investment opportunity, Senolytx's focus on addressing unmet medical needs and its progressive approach to tackling age-related diseases make it an attractive prospect for venture capitalists seeking to invest in impactful healthcare innovations.

Taxonomy: pharmaceuticals, medicine development, clinical trials, aging-associated diseases, cell targeting therapy, Boston, Barcelona, therapeutics, innovation, biomedical technology

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Grant •••••• 1 •••• •••• 01 Aug 2018
Seed Round •••••• - 07 Aug 2017

Senolytx Alternatives & Competitors

Senolytx vs

Transforms landscapes though creative solutions, resulting in dynamic spaces that are seamlessly int...

14 employees
Senolytx vs
STX Engine
STX Engine Korea South

Since STX Engine launched as a diesel engine manufacturer in 1976, it has been absolutely filling th...

340 employees
Manufacturing
Senolytx vs
STX Entertainment
STX Entertainment United States

Fully integrated, diversified, global media company

Acquired
83 employees

FAQ About Senolytx

STX develops medicines targeting damaged cells to improve human health and advance therapies to clinical trials for aging-associated diseases.
Senolytx was founded in 2017.
Senolytx is headquartered in Spain.
Senolytx operates in the following industries: Biopharma, Biotechnology, Medical Devices, Pharmaceutical, Robotics.
Senolytx has approximately 2 employees.
Senolytx has completed 2 funding rounds, raising a total of $571.43K. The latest funding stage is Grant.
Top alternatives and competitors to Senolytx include STX Landscape Architects, STX Engine, STX Entertainment, STX Commodities, Scorpion Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Senolytx and STX Landscape Architects are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Senolytx and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

One analytics cookie (Google Analytics). Cookie Policy